Subscribe To
OCS / Oculis to Present a Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 DIAMOND Trial Results for Diabetic Macular Edema
OCS News
By GlobeNewsWire
October 5, 2023
Oculis to Present a Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 DIAMOND Trial Results for Diabetic Macular Edema
ZUG, Switzerland, and BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharm more_horizontal
By Proactive Investors
June 9, 2023
Oculis could have a breakthrough treatment on its hands with an eye drop for DME
Oculis is an “under-the-radar” biotech stock that is off to a strong start thanks to a lead drug candidate that could offer hope for diabetic macu more_horizontal